Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

Nanoparticle-based vaccine for mucosal protection against Shigella flexneri in mice.

Camacho AI, Irache JM, de Souza J, Sánchez-Gómez S, Gamazo C.

Vaccine. 2013 Jul 11;31(32):3288-94. doi: 10.1016/j.vaccine.2013.05.020. Epub 2013 May 31.

PMID:
23727423
2.

Mucosal immunization with Shigella flexneri outer membrane vesicles induced protection in mice.

Camacho AI, de Souza J, Sánchez-Gómez S, Pardo-Ros M, Irache JM, Gamazo C.

Vaccine. 2011 Oct 26;29(46):8222-9. doi: 10.1016/j.vaccine.2011.08.121. Epub 2011 Sep 10.

PMID:
21911022
3.

Towards a non-living vaccine against Shigella flexneri: from the inactivation procedure to protection studies.

Camacho AI, Souza-Rebouças J, Irache JM, Gamazo C.

Methods. 2013 May 1;60(3):264-8. doi: 10.1016/j.ymeth.2012.09.008. Epub 2012 Oct 6.

PMID:
23046911
4.

Multi-serotype outer membrane vesicles of Shigellae confer passive protection to the neonatal mice against shigellosis.

Mitra S, Chakrabarti MK, Koley H.

Vaccine. 2013 Jun 28;31(31):3163-73. doi: 10.1016/j.vaccine.2013.05.001. Epub 2013 May 15.

PMID:
23684822
5.

Shigella outer membrane protein PSSP-1 is broadly protective against Shigella infection.

Kim JO, Rho S, Kim SH, Kim H, Song HJ, Kim EJ, Kim RY, Kim EH, Sinha A, Dey A, Yang JS, Song MK, Nandy RK, Czerkinsky C, Kim DW.

Clin Vaccine Immunol. 2015 Apr;22(4):381-8. doi: 10.1128/CVI.00661-14. Epub 2015 Feb 4.

6.

Effective protection of mice against Shigella flexneri with a new self-adjuvant multicomponent vaccine.

Pastor Y, Camacho A, Gil AG, Ramos R, Ceráin AL, Peñuelas I, Irache JM, Gamazo C.

J Med Microbiol. 2017 Jul;66(7):946-958. doi: 10.1099/jmm.0.000527. Epub 2017 Jul 19.

PMID:
28721849
7.

Evaluation of immunogenicity and protective efficacy of orally delivered Shigella type III secretion system proteins IpaB and IpaD.

Heine SJ, Diaz-McNair J, Martinez-Becerra FJ, Choudhari SP, Clements JD, Picking WL, Pasetti MF.

Vaccine. 2013 Jun 19;31(28):2919-29. doi: 10.1016/j.vaccine.2013.04.045. Epub 2013 May 2.

8.

Development of a cost-effective vaccine candidate with outer membrane vesicles of a tolA-disrupted Shigella boydii strain.

Mitra S, Sinha R, Mitobe J, Koley H.

Vaccine. 2016 Apr 4;34(15):1839-46. doi: 10.1016/j.vaccine.2016.02.018. Epub 2016 Feb 12.

PMID:
26878295
9.

Safety and immunogenicity of a Shigella flexneri 2a Invaplex 50 intranasal vaccine in adult volunteers.

Tribble D, Kaminski R, Cantrell J, Nelson M, Porter C, Baqar S, Williams C, Arora R, Saunders J, Ananthakrishnan M, Sanders J, Zaucha G, Turbyfill R, Oaks E.

Vaccine. 2010 Aug 23;28(37):6076-85. doi: 10.1016/j.vaccine.2010.06.086. Epub 2010 Jul 7.

PMID:
20619378
11.

Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine.

Oaks EV, Turbyfill KR.

Vaccine. 2006 Mar 20;24(13):2290-301. Epub 2005 Dec 5.

PMID:
16364513
12.

Construction of a multivalent vaccine strain of Shigella flexneri and evaluation of serotype-specific immunity.

Jennison AV, Roberts F, Verma NK.

FEMS Immunol Med Microbiol. 2006 Apr;46(3):444-51.

13.

Intradermal delivery of Shigella IpaB and IpaD type III secretion proteins: kinetics of cell recruitment and antigen uptake, mucosal and systemic immunity, and protection across serotypes.

Heine SJ, Diaz-McNair J, Andar AU, Drachenberg CB, van de Verg L, Walker R, Picking WL, Pasetti MF.

J Immunol. 2014 Feb 15;192(4):1630-40. doi: 10.4049/jimmunol.1302743. Epub 2014 Jan 22.

14.

Parenteral immunization with IpaB/IpaD protects mice against lethal pulmonary infection by Shigella.

Martinez-Becerra FJ, Scobey M, Harrison K, Choudhari SP, Quick AM, Joshi SB, Middaugh CR, Picking WL.

Vaccine. 2013 May 31;31(24):2667-72. doi: 10.1016/j.vaccine.2013.04.012. Epub 2013 Apr 16.

PMID:
23602665
15.

Outer membrane protein A (OmpA) of Shigella flexneri 2a, induces protective immune response in a mouse model.

Pore D, Mahata N, Pal A, Chakrabarti MK.

PLoS One. 2011;6(7):e22663. doi: 10.1371/journal.pone.0022663. Epub 2011 Jul 26.

16.

Outer membrane vesicles of Shigella boydii type 4 induce passive immunity in neonatal mice.

Mitra S, Barman S, Nag D, Sinha R, Saha DR, Koley H.

FEMS Immunol Med Microbiol. 2012 Nov;66(2):240-50. doi: 10.1111/j.1574-695X.2012.01004.x. Epub 2012 Aug 1.

17.

Safety and Immunogenicity of a Candidate Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: a Single-Blind, Randomized Phase I Study.

Riddle MS, Kaminski RW, Di Paolo C, Porter CK, Gutierrez RL, Clarkson KA, Weerts HE, Duplessis C, Castellano A, Alaimo C, Paolino K, Gormley R, Gambillara Fonck V.

Clin Vaccine Immunol. 2016 Dec 5;23(12):908-917. Print 2016 Dec.

18.

Immunogenicity and protective efficacy offered by a ribosomal-based vaccine from Shigella flexneri 2a.

Shim DH, Chang SY, Park SM, Jang H, Carbis R, Czerkinsky C, Uematsu S, Akira S, Kweon MN.

Vaccine. 2007 Jun 15;25(25):4828-36. Epub 2007 Apr 20.

PMID:
17507120
19.
20.

Role of Shigella flexneri 2a 34 kDa outer membrane protein in induction of protective immune response.

Mukhopadhaya A, Mahalanabis D, Chakrabarti MK.

Vaccine. 2006 Aug 14;24(33-34):6028-36. Epub 2006 Mar 31.

PMID:
16765491

Supplemental Content

Support Center